Mesenchymal stem cell therapy for neurological disorders - Medipost
Alternative Names: Neurostem; Neurostem-ADLatest Information Update: 22 Mar 2023
At a glance
- Originator Medipost
- Class Antidementias; Mesenchymal stem cell therapies; Neural stem cell therapies; Neuroprotectants
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Alzheimer's disease
- No development reported Amyotrophic lateral sclerosis; Stroke
Most Recent Events
- 18 Mar 2022 Medipost completes a phase I/II follow-up trial for Alzheimer's disease in South Korea (NCT03172117)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Intracerebral, Injection)
- 12 Jul 2021 Samsung Medical Center plans a clinical trial for Alzheimer's Disease in South Korea (Intraventricular) (NCT04954534)